Insider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells 400 Shares of Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 400 shares of the firm’s stock in a transaction on Monday, April 14th. The shares were sold at an average price of $68.96, for a total transaction of $27,584.00. Following the transaction, the vice president now directly owns 80,145 shares of the company’s stock, valued at $5,526,799.20. The trade was a 0.50 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Meredith Cook also recently made the following trade(s):

• On Thursday, March 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $63.33, for a total transaction of $25,332.00.
• On Thursday, February 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $59.54, for a total value of $23,816.00.

ANI Pharmaceuticals Price Performance

ANI Pharmaceuticals stock opened at $69.55 on Wednesday. ANI Pharmaceuticals, Inc. has a 12-month low of $52.50 and a 12-month high of $70.00. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The firm has a 50-day moving average price of $62.71 and a 200-day moving average price of $59.22. The firm has a market capitalization of $1.51 billion, a PE ratio of -126.45 and a beta of 0.49.

Analyst Ratings Changes

ANIP has been the subject of several research analyst reports. StockNews.com cut ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, April 8th. JPMorgan Chase & Co. began coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, March 12th. They issued an “overweight” rating and a $85.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, March 17th. Jefferies Financial Group initiated coverage on shares of ANI Pharmaceuticals in a research note on Friday, March 14th. They issued a “buy” rating and a $80.00 price objective for the company. Finally, Guggenheim restated a “buy” rating and set a $86.00 target price on shares of ANI Pharmaceuticals in a research report on Friday, April 11th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, ANI Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $79.75.

Institutional Trading of ANI Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its holdings in shares of ANI Pharmaceuticals by 159.3% in the third quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company’s stock worth $33,101,000 after buying an additional 340,854 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of ANI Pharmaceuticals by 14.6% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 15,442 shares of the specialty pharmaceutical company’s stock worth $854,000 after purchasing an additional 1,972 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of ANI Pharmaceuticals by 4.2% during the third quarter. Geode Capital Management LLC now owns 425,225 shares of the specialty pharmaceutical company’s stock valued at $25,373,000 after purchasing an additional 17,314 shares during the period. Franklin Resources Inc. boosted its stake in shares of ANI Pharmaceuticals by 6.1% during the third quarter. Franklin Resources Inc. now owns 12,057 shares of the specialty pharmaceutical company’s stock valued at $705,000 after purchasing an additional 691 shares during the period. Finally, Barclays PLC grew its holdings in shares of ANI Pharmaceuticals by 1,681.2% in the third quarter. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company’s stock worth $8,534,000 after purchasing an additional 135,003 shares during the last quarter. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.